ArticleCancer reports (Hoboken, N.J.)2026
Surgical Management of Bone Metastases in Bladder Cancer: A Single-Center Retrospective Study.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeBladder cancer (BC) frequently spreads to the bone, resulting in skeletal-related events with a major effect on quality of life. Since surgical treatment for bone metastases (BM) in BC patients remains understudied, we aimed to evaluate the outcome of surgery in a case series of 20 consecutive patients. PATIENTS AND
methodsA retrospective of BC patients surgically treated for BM at our center between 2007 and 2024. Patient characteristics, surgical procedures, and outcomes, as well as postoperative survival, were analyzed.
resultsOf the 20 patients with BC, who were operated for BM, 14 (70%) were male, with a median age at diagnosis of BM of 72 years. The femur was the most commonly metastatic site (55%), followed by the pelvis (20%) and tibia (15%). The median time between BC diagnosis and surgery for BM was 18 months, and the most frequent event was a complete pathological fracture (70%). Prosthetic joint reconstruction was used for 10 (50%) of our patients, making it the most commonly used procedure in our cohort. Seven patients experienced postoperative complications, and two underwent reoperation. Median postoperative survival was 2 months, and only two patients were alive at last follow-up, both of them presenting with BM many years after initial BC diagnosis.
conclusionMost BM in BC are in the lower extremity and pelvis and are lytic in character. The oncological outcome is poor, with short postoperative survival. The choice of surgical method should take into account the generally palliative stage of the disease. Patients presenting with late BM may have a better prognosis and thus benefit from more advanced surgical reconstruction. Surgery can provide symptomatic relief and structural stabilisation, but the risk for postoperative complications is considerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.